Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.
|Articles|February 26, 2014
- NSCLC (Issue 2)
- Volume 2
- Issue 1
PD-L1 as a Biomarker for Immunotherapy Agents in Lung Cancer
Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses PD-L1 as a potential biomarker for immunotherapy agents for patients with lung cancer.
Advertisement
Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses PD-L1 as a potential biomarker for immunotherapy agents for patients with lung cancer.
Read more aboutfrontline treatment considerations for lung cancer > >
Articles in this issue
over 12 years ago
Crizotinib Resistance in ALK-Positive Lung Cancerover 12 years ago
Clinical Update: ALK-Positive NSCLCover 12 years ago
Treating Older Patients With NSCLCover 12 years ago
Treatment of Elderly Patients With NSCLCover 12 years ago
Current Challenges in Molecular Testing in NSCLCover 12 years ago
Individualized Maintenance Therapy for NSCLCover 12 years ago
Frontline Treatment Considerations in Non-Small Cell Lung CancerAdvertisement
Related to this article
FYB206 is being reviewed as a pembrolizumab biosimilar after meeting pharmacokinetic equivalence; no additional efficacy trial is required.
During a live event, Mary Jo Fidler, MD, and participants discussed how an intermediate-risk regimen, insurance resistance, and limited experience with trilaciclib shape neutropenia prevention in extensive-stage disease.
For Hispanic Heritage Month, Narjust Florez, MD, discusses lung cancer risk, biomarker testing, and trial access in Hispanic and Latinx patients.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Selpercatinib Shows Durable Responses in Pediatric Solid Tumors
3
Male Sex, Age, and Tumor Genetics Linked to Thyroid Cancer Mortality
4
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
5